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Objective: Acute stroke remains a medical emergency even during the COVID-19 pandemic. Most patients with
COVID-19 infection present with constitutional and respiratory symptoms; while others present with atypical
gastrointestinal, cardiovascular, or neurological manifestations. Here we present a series of four patients with
COVID-19 that presented with acute stroke.
Methods: We searched the hospital databases for patients that presented with acute stroke and concomitant
features of suspected COVID-19 infection. All patients who had radiographic evidence of stroke and PCR-conﬁrmed COVID-19 infection were included in the study. Patients admitted to the hospital with PCR- conﬁrmed
COVID-19 disease whose hospital course was complicated with acute stroke while inpatient were excluded from
the study. Retrospective patient data were obtained from electronic medical records. Informed consent was
obtained.
Results: We identiﬁed four patients who presented with radiographic conﬁrmation of acute stroke and PCRconﬁrmed SARS-CoV-2 infection. We elucidate the clinical characteristics, imaging ﬁndings, and the clinical
course.
Conclusions: Timely assessment and hyperacute treatment is the key to minimize mortality and morbidity of
patients with acute stroke. Stroke teams should be wary of the fact that COVID-19 patients can present with
cerebrovascular accidents and should dawn appropriate personal protective equipment in every suspected patient. Further studies are urgently needed to improve current understandings of neurological pathology in the
setting of COVID-19 infection.

1. Introduction
In December 2019, the ﬁrst reports of the Corona Virus Disease
2019 (COVID-19) – an illness caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – emerged from
Wuhan, Hubei Province, China (Li et al., 2020). Since then, this disease
has become a worldwide pandemic, with over two-hundred thousand
deaths to date (WHO, 2020; COVID-19, 2020). Symptoms of SARS-Cov2 infection range from asymptomatic disease to life-threatening acute
respiratory distress syndrome (ARDS), severe pneumonia, acute kidney
injury (AKI), myocarditis, eventual multi-organ failure, and death
(Huang et al., 2020; Inciardi et al., 2020). Recent literature reported
multiple neurological manifestations including cerebrovascular accidents in patients with severe infection (Mao et al., 2020). So far, there

⁎

are no reported cases of COVID-19 presenting with strokes in the literature. Here, we report a case series of four patients that presented
with ischemic stroke in the setting of PCR-conﬁrmed SARS-CoV-2 infection.
2. Methods
We searched the hospital database for patients that presented with
radiographic conﬁrmation of acute stroke and concomitant features of
suspected COVID-19 infection. All patients who had radiographic evidence of stroke and PCR-conﬁrmed COVID-19 infection were included
in the study. Patients admitted to the hospital with PCR-conﬁrmed
COVID-19 disease whose hospital course was complicated with acute
stroke while inpatient were excluded from the study. Retrospective
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Table 1
Pertinent laboratory ﬁndings.
Laboratory Findings

Patient 1

Patient 2

Patient 3

Patient 4

White blood cell count (4.8–10.8 K/
μL)
Neutrophils (1.4–6.5 K/μL)
Lymphocytes (1.2–3.4 K/μL)
Platelet count (130–400 per mm3)
Hemoglobin (12–16 g/dL)
Albumin (3.5–5.2 g/dL)
Alanine aminotransferase (0–41 U/
L)
Aspartate aminotransferase
(0–41 U/L)
Lactate dehydrogenase (50–242 U/
L)
Creatinine (0.7–1.5 mg/dL)
Cardiac Troponin T (< 0.01 pg/ml)
Prothrombin Time (9.95–12.87 s)
Activated partial thromboplastin
time (27–39.2 s)
D-Dimer (0–230 ng/mL)
Ferritin (15–150 ng/L)
Procalcitonin (0.02–0.10 ng/mL)
C-reactive protein (0.00–0.40 mg/
dL)
IL-6 (0–6.3 pg/mL)

12.32

4.95

18.89

7.5

10.95
0.67
182
15.5
2.7
55

3.41
1.07
138
15.1
4.1
25

16.36
1.15
380
12.9
3.2
18

5.3
1.5
176
11.6
2.9
14

47

31

34

18

NA

NA

712

200

1.1
< 0.01
19.70
27.6

1
< 0.01
13.5
27.2

1.6
0.11
15.2
38.2

1.8
0.14
13.5
27.7

NA
NA
14
26.22

NA
NA
NA
NA

13,966
891
0.49
16.24

3442
135.9
0.08
12.7

NA

NA

NA

8.5

Fig. 1a. A CT of the head demonstrating loss of gray-white diﬀerentiation at the
left occipital and parietal lobes, consistent with acute infarct.

Notes: The ﬁrst available laboratory data are presented here. NA: Not available.

patient data was obtained from electronic medical records. Informed
consent was obtained.
3. Results
We identiﬁed four patients who presented with radiographic evidence of acute stroke and PCR-conﬁrmed COVID-19 disease. We elucidate the clinical characteristics, imaging ﬁndings, and clinical course.
Laboratory data are presented in Table 1.

Fig. 1b. CT chest demonstrating bilateral peripheral dominant patchy airspace
opacities and diﬀuse ground glass opacities, characteristic for atypical pneumonia/viral infection from COVID-19.

pursue comfort measures and terminally extubated the patient.

3.1. Patient 1

3.2. Patient 2

73-year-old male with a past medical history of hypertension, dyslipidemia, and carotid stenosis presented to the emergency department
(ED) with fever, respiratory distress, and altered mental status. Review
of systems was positive for dyspepsia, nausea, vomiting, reduced oral
intake for two days, and negative for fevers or chills at home. He had a
sick contact at home. Vital signs on presentation were fever of 101° F
(38.3° C), tachycardia with heart rate (HR) of 102, hypoxemia with
saturation of 85% on 100% non-rebreather mask. The patient was intubated in the ED for hypoxemic respiratory failure. A computed tomography (CT) scan of the head was performed for altered mental
status, which demonstrated loss of gray-white diﬀerentiation at the left
occipital and parietal lobes, consistent with acute infarct (Fig. 1a). CT of
the chest demonstrated bilateral peripheral patchy airspace opacities
and diﬀuse ground-glass opacities, characteristic for atypical pneumonia/viral infection from COVID-19 (Fig. 1b). Electrocardiogram
(EKG) was within normal limits. Blood work was signiﬁcant for leukocytosis with lymphopenia. Urine analysis was within normal limits.
C-reactive protein was elevated to 26 mg/dl (0–0.4 mg/dl). D-Dimer
was not checked during the hospital course. COVID-19 polymerase
chain reaction (PCR) detected the virus. Blood and urine cultures did
not yield any growth. A repeat CT of the head demonstrated progression
toward a large acute infarct of the left MCA territory with hyperdense
appearance of left MCA vessels - consistent with an acute thrombus. The
patient was deemed not a candidate for thrombolysis or neuro-intervention due to poor functional status. The patient was treated with
aspirin and other supportive measures. No abnormal heart rhythm was
noted on telemetry monitoring. The family eventually decided to

83-year-old female with a past medical history of frequent urinary
tract infections, hypertension, hyperlipidemia, diabetes mellitus type 2,
and neuropathy presented to the ED with fever, facial droop, slurred
speech, and reduced oral intake. Initial vital signs were signiﬁcant for
temperature of 101.4° F (38.6° C), HR of 94, blood pressure (BP) of
172/64, saturating 94% on room air. The examination was signiﬁcant
for left facial droop and slurred speech with no other signiﬁcant neurological deﬁcits. National Institute of Health Stroke Scale (NIHSS) was
calculated to be 2. Blood work was signiﬁcant for leucopenia with
lymphopenia. Urine analysis was within normal limits, chest X-Ray
showed bilateral peripheral opacities. CT head was negative for any
acute changes. CTA of head and neck demonstrated no large vessel
occlusion, with focal moderate stenosis of right MCA (Fig. 2a), and
incidental pulmonary ground-glass opacities in bilateral apices. COVID19 was suspected given the fevers and CT ﬁndings. COVID-19 PCR
detected the virus. D-Dimer and other inﬂammatory markers were not
checked. CXR progressively worsened with bilateral inﬁltrates (Fig. 2b).
Urine and blood cultures did not yield any growth. No arrhythmias
were noted during the hospitalization. On day 3 of hospitalization, the
patient developed left-sided hemineglect, worsening left-sided facial
droop with left hemiparesis. The speech was normal. NIHSS was calculated to be 16. Repeat CT of the head demonstrated a new moderate
hypodensity in the right frontal lobe representing acute infarct (Fig. 2c).
The patient was deemed too high risk for thrombolysis or neuro-intervention. A CT angiogram was planned prior to starting Integrellin,
116
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Fig. 3a. CT head demonstrating acute right MCA stroke.

Fig. 2a. CTA of head and neck demonstrated no large vessel occlusion, focal
moderate stenisis of right MCA.

Fig. 3b. CTA of the head and neck demonstrating occlusion of the right internal
carotid artery at origin.

101, BP 130/77, Examination was signiﬁcant for left hemiplegia and
aphasia. NIHSS was calculated to be 36. CT head revealed an acute
right MCA stroke (Fig. 3a). CTA of the head and neck demonstrated
occlusion of the right internal carotid artery at origin and incidental
bilateral patchy apical lung opacities (Fig. 3b). CT perfusion demonstrated a 305 cc core infarct in the right MCA distribution and a surrounding 109 cc ischemic penumbra (Fig. 3c). The patient was deemed
not a suitable candidate for any acute neuro-intervention due to the
large core infarct. Considering these characteristic CT ﬁndings, the
patient was tested for COVID-19 infection with PCR and was positive.
Laboratory data on admission demonstrated leukocytosis with lymphopenia, elevated d-dimer (13966 ng/ml DDU), along with elevated
lactate dehydrogenase (712 U/L) and elevated C – reactive protein
(16.24 mg/dl). The patient’s hospital course was complicated by acute
kidney injury and progressively increasing oxygen requirements. On the
third day of admission, her family chose for terminal extubation with
comfort measures.

Fig. 2b. CXR demonstrating worsening bilateral opacities.

Fig. 2c. CT of the head demonstrated new moderate hypodensity in the right
frontal lobe representing acute infarct.

however her respiratory status worsened, requiring intubation and
mechanical ventilation. Soon after, the family decided to withdraw
care.
3.3. Patient 3
80 year-old-female with a history of hypertension was brought to
the ED for a chief complaint of altered mental status and left-sided
weakness. The family denied history of fever or cough, but reported
that the patient has been falling frequently in the past week. The patient
was intubated for airway protection and a code stroke was activated.
Vital signs in the ED were signiﬁcant for Temp of 100.2° F (37.9° C), HR

Fig. 3c. CT perfusion demonstrating large core infarct.
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disease, and previous cerebrovascular disease (Li et al., 2020). Average
time of onset of stroke after COVID-19 diagnosis was 12 days (Li et al.,
2020). Elevated levels of CRP and D-dimer, indicating a high inﬂammatory state and abnormalities with the coagulation cascade, respectively, might play a role in the pathophysiology of stroke in the
setting of COVID-19 infection (Li et al., 2020). Despite these reports, all
four cases here presented with a cerebrovascular accident in early
stages of their illness.
The SARS-CoV-2 virus is the seventh known variant of coronavirus
that infects humans (Corman et al., 2019). SARS-CoV-2 is genetically
similar to SARS-CoV-1 (Wu et al., 2020). SARS-CoV-1 in 2003 aﬀected
about 8000 patients with few reports of neurological manifestations mostly peripheral neuropathy and encephalitis (Tsai et al., 2005). Similar to SARS-CoV-1, the current SARS-CoV-2 aﬀects the neurological
system in about 36.7% of patients as per Mao et al. (Mao et al., 2020).
Most coronaviruses are neurotropic, and others speculate that SARSCoV-2 is neurotropic too (Steardo et al., 2020). Furthermore, there are
reports of SARS-CoV-2 being identiﬁed in cerebrospinal ﬂuid by PCR
(Moriguchi et al., 2020). Angiotensin converting enzyme-2 (ACE) receptors are the major entry points for SARS-Cov-2 and other coronaviruses (Hoﬀmann et al., 2020). Although ACE-2 receptors are
present in the nervous system, alternate pathways have been proposed
to explain the entry of SARS-CoV-2 into the nervous system, including
direct injury to the blood and blood brain barrier, hypoxic injury, and
immune-related injury (Steardo et al., 2020; Wu et al., 2020).
The exact pathophysiology behind these cerebrovascular accidents
is still to be determined. Recent bacterial or viral infections have been
known to cause strokes by increasing the risks for cardioembolic as well
as arterio-arterial embolic events (Grau et al., 1998). A recent study
from the Netherlands by Klock et al. demonstrated that 31% of critically
ill ICU patients develop thrombotic complications (Kloka et al., 2020).
Another study looking at activated partial thromboplastin time-based
clot waveform analysis (CWA) in COVID-19 patients concluded that
CWA parameters demonstrate hypercoagulability that precedes or coincides with severe illness (Tan et al., 2020). Multiple reports of pulmonary emboli are currently available in the literature (Danzi et al.,
2020). Autopsy and pathology ﬁndings are scarcely available, but recent autopsy ﬁndings suggest thrombotic microangiopathy in multiple
organs especially in the lungs and kidney (Fox et al., 2020; Barton et al.,
2020; Yao et al., 2020). No autopsy reports of the brain are available at
the time of this writing. With this evidence, the likely mechanism of
early cerebrovascular accidents could be hypercoagulability leading to
macro and micro thrombi formation in the vessels. Other pathophysiology could be directly related to the infection or hypoxia. Further
studies are urgently needed for a comprehensive understanding of the
neurological pathology of COVID-19 and its eﬀects on the nervous
system.

Fig. 4a. MRI of the brain demonstrating acute infarct in the left medial temporal lobe.

3.4. Patient 4
An 88-year-old female with a past medical history of hypertension,
chronic kidney disease, and hyperlipidemia presented to the ED with a
transient 15-minute episode of right arm weakness and numbness along
with word-ﬁnding diﬃculty. Vital signs on presentation were within
normal limits. The initial neurological examination was normal. Code
stroke was activated. CT head did not show any acute ﬁndings. EKG
showed normal sinus rhythm. Thrombolysis was deferred, and she was
admitted with a diagnosis of transient ischemic attack. As the patient
complained of mild shortness of breath with dry cough, Covid-19 PCR
was sent, which detected the virus. D-Dimer (< 880 ng/ml) was elevated to 3,442 ng/ml, and other inﬂammatory markers were elevated
as well. Magnetic Resonance Imaging (MRI) showed an acute infarct in
the left medial temporal lobe (Fig. 4a). Magnetic resonance angiogram
(MRA) of the head and neck revealed mild stenosis of the right M1
segment (Fig. 4b). No arrhythmias were noted on telemetry. Patient
was treated with aspirin, statins, and was discharged to a rehab facility
with an event monitor.

4. Discussion
To our knowledge, this is the ﬁrst series of cases with PCR conﬁrmed COVID-19 infection presenting with a cerebrovascular accident.
In the study of Mao et al., 5.7% of patients with severe infection developed cerebrovascular disease later in the course of illness (Mao et al.,
2020). In a study by Li Y et al., the incidence of stroke in COVID-19
patients was about 5% with a median age of 71.6 years (Li et al., 2020).
These patients were associated with severe disease and had a higher
incidence of risk factors like hypertension, diabetes, coronary artery

5. Treatment implications
The COVID-19 pandemic necessitates that extra measures be taken
to provide and care for stroke patients, along with measures aimed at
minimizing the spread of infection. Some of the challenges we encounter with acute stroke patients include their inability to eﬀectively
communicate due to speech problems, altered mental status, inadequate history (because of the limitations on visitors by hospital
policies), etc.
Khosravani. et al. proposed a Protected Code Stroke (PCS) concept
during this pandemic which provides a framework for key elements like
screening guidelines, PPE, and crisis resource management (Khosravani
et al., 2020). Based on previous studies, recommendations for PCS include: Paramedics should develop an infectious screening policy on all
patients with stroke-like presentations, before bringing them to the
hospital (Khosravani et al., 2020). Outside transfers should be minimized, and even the ones that need transfer should have an infectious
screening before the transfer (Khosravani et al., 2020). A dedicated

Fig. 4b. MRA of the head and neck demonstrating mild stenosis of right M1
segment.
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neurology hot-spot along with a mobile CT unit for COVID-19 patients
with stroke-like symptoms is beneﬁcial (Umapathi et al., 2004). Clinically stable patients after thrombolysis can be monitored on non-intensive care units (Umapathi et al., 2004).
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6. Conclusion
Stroke teams should be wary of the fact that COVID-19 patients can
present with cerebrovascular accidents and dawn appropriate personal
protective equipment in every suspected patient. Plans should be developed not to neglect the management of acute cerebrovascular accidents, even though the control of COVID-19 infection is our biggest
priority. More research is needed to identify the neurological implications of COVID-19 disease.
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